0.25 tirzepatide Mounjaro 2.5 mg and Wegovy mg Compared lose 15 Mounjaro Tirzepatide 4 Pens Of

Assessed 1 May 2020

Participants using once-weekly subcutaneous semaglutide 2.4 mg lost a mean of 14.9% of body weight versus 2.4% in the placebo group over 68 weeks

The data suggests caution

Priority Applications (2) Applications Claiming Priority (2) Publications (1) Family ID=85155356 Family Applications (1) Country Status (3) Citations (5) Family Cites Families (4) 2022 2022-08-04 US US18/294,556 patent/US20260042809A1/en active Pending 2022-08-04 WO PCT/IN2022/050702 patent/WO2023012829A1/en not_active Ceased 2022-08-04 EP EP22852521.8A patent/EP4380962A4/en active Pending

Drugs with three targets are also in the pipeline, including retatrutide, Lillys triple GLP-1, GIP and glucagon agonist combination

Easy berberine patches that deliver active ingredients through your skin to support natural GLP-1 activity and metabolic balance, no nausea